



# GUJARAT THEMIS BIOSYN LIMITED

**CIN: L24230GJ1981PLC004878**

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: [hrm@gtbl.in](mailto:hrm@gtbl.in)

GTBL/BSE/NSE/2026-27/05

23<sup>rd</sup> April, 2026

**Corporate Relationship Department  
BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code – 506879

**Listing Department  
National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400051  
Symbol: GUJTHEM

Dear Sir / Madam,

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

In compliance with Regulation 30 of Listing Regulations read with SEBI Master Circular dated January 30, 2026, we are pleased to inform you that Gujarat Themis Biosyn Limited (‘Company’) has signed an Asset Purchase Agreement with Sanofi, French holding Company of the Sanofi group headquartered in Paris, for acquiring a portfolio of anti-tuberculosis (TB) and anti-infective brands along with the associated trademark rights subject to the satisfaction of customary closing conditions & receipt of regulatory & other approvals. The details of the Acquisition are as under:

**Name of the Acquirer – Gujarat Themis Biosyn Limited**

a)	Name of the target entity, details in brief such as size, turnover etc.;	The Seller is Sanofi, French holding Company of the Sanofi group headquartered in Paris.  The Company has entered into an Asset Purchase Agreement for acquisition of 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The concerned portfolio reported net sales of approximately EURO 62 million for the year ended 2025.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	No. It is not a related party transaction.
c)	Industry to which the entity being acquired belongs;	Pharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	This Asset Purchase represents a significant step in GTBL’s strategy to strengthen its global generic pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong

**MUMBAI OFFICE:** Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104

Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: [gtblmumbai@gtbl.in](mailto:gtblmumbai@gtbl.in) Website Address: [www.gtbl.in](http://www.gtbl.in)



# GUJARAT THEMIS BIOSYN LIMITED

**CIN: L24230GJ1981PLC004878**

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: [hrm@gtbl.in](mailto:hrm@gtbl.in)

		opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realizations across the value chain.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions and other clearances
f)	Indicative time period for completion of the acquisition;	It is expected that this Asset Purchase will be closed by the end of December 2026
g)	Consideration - whether cash consideration or share swap or any other form and details of the same	Consideration for the transaction is Euro 158 Million payable in cash at closing
h)	Cost of acquisition and/or the price at which the shares are acquired	Euro 158 million
i)	Percentage of shareholding/control acquired and/or number of shares acquired	Not Applicable
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Acquisition of 13 established branded generic products with a strong presence across more than 55 countries, including Europe, the Middle East and Africa from the Seller, Sanofi, French holding Company of the Sanofi group headquartered in Paris. The acquisition will include marketing authorizations, brands, regulatory dossiers and inventory and associated commercial rights. The transaction does not involve the acquisition of any legal entity, manufacturing facilities or employees, making it a capital-efficient and asset-light expansion for Gujarat Themis Biosyn Limited  Revenues from the 13 established branded generic products in the last 3 years were: -  FY23 - Euro 66 million; FY24 – Euro 67 million; and FY25 – Euro 62 million.

The above is for your information and dissemination please.

Thanking you,  
Yours faithfully,

For **Gujarat Themis Biosyn Limited**

**Vineet Gawankar**  
**Company Secretary & Compliance Officer**